- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01270295
Soluble Forms and Ligands of RAGE in ALI/ARDS (SoLiRAGE). (SoLiRAGE)
Soluble Forms and Ligands of the Receptor for Advanced Glycation End Products (RAGE) in the Pulmonary Edema Fluid and Plasma From ICU Patients With ALI/ARDS : an Observational Prospective Study.
Studienübersicht
Status
Detaillierte Beschreibung
BACKGROUND:
The receptor for advanced glycation end products (RAGE) is now identified as a marker of alveolar type I cell injury. RAGE is a member of the immunoglobulin superfamily that acts as a multiligand receptor and is involved in propagating inflammatory responses. While the precise function of RAGE remains unclear, the elevated levels of RAGE, and its soluble isoform sRAGE, correlate with severity of ALI/ARDS in human and animal studies, and RAGE levels could reflect impaired alveolar fluid clearance. Frequently, the biology of RAGE coincides with settings in which ligands of the receptor accumulate, especially in a proinflammatory environment. More work is needed for us to understand the mechanisms by which RAGE is regulated during ALI/ARDS, especially with regard to the expression of its soluble forms and the involvement of its potential ligands.
DESIGN NARRATIVE:
This observational prospective clinical study will describe and compare soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in the alveolar edema fluid and in the plasma from ICU patients enrolled within the first 24 hours after onset of ALI/ARDS, and from patients under mechanical ventilation (control group).
Edema fluid and plasma samples will be collected simultaneously on day 1, day 3 and day 6, in order to describe kinetics of evolution of soluble forms and ligands of RAGE levels. Undiluted pulmonary edema fluid samples will be collected in intubated patients only, and blood samples will be simultaneously gathered from indwelling arterial and central venous catheters. The concentrations of soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) will be measured in duplicate by ELISA.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Clermont-Ferrand, Frankreich, 63003
- CHU Clermont-Ferrand
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- ICU patients under mechanical ventilation
- Patients within the first 24 hours after onset of ALI/ARDS according to the 1994 American-European Consensus Conference (AECC)
Exclusion Criteria:
- Pregnancy
- Acute exacerbation of diabetes
- Dialysis for end-stage kidney disease
- Alzheimer's disease
- Amyloidosis
- Evolutive neoplastic lesion
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in the plasma from ICU patients within the first 24 hours after onset of ALI/ARDS
Zeitfenster: within the first 24 hours after onset of ALI/ARDS
|
within the first 24 hours after onset of ALI/ARDS
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To describe kinetics of evolution of soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in ICU patients with or without ALI/ARDS: biomarkers levels in pulmonary edema fluid and plasma on day 1, day 3, and day 6
Zeitfenster: on day 1, day 3, and day 6
|
on day 1, day 3, and day 6
|
To describe the plasma and pulmonary levels of soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) in the setting of ALI/ARDS.
Zeitfenster: on day 1, day 3, and day 6.
|
on day 1, day 3, and day 6.
|
To test the correlation between soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels and net alveolar fluid clearance in patients within the first 24 hours after onset of ALI/ARDS.
Zeitfenster: within the first 24 hours after onset of ALI/ARDS
|
within the first 24 hours after onset of ALI/ARDS
|
To decribe venous-to-arterial differences in soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels during ALI/ARDS. -
Zeitfenster: on day 1, day 3, and day 6.
|
on day 1, day 3, and day 6.
|
To test the correlation between biomarkers levels (soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs)) and CT-scan lung morphology in patients within the first 24 hours after onset of ALI/ARDS
Zeitfenster: within the first 24 hours after onset of ALI/ARDS
|
within the first 24 hours after onset of ALI/ARDS
|
To describe soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in ICU patients under mechanical ventilation (MV), in order to assess the influence of MV on these markers: biomarkers levels in pulmonary edema fluid and plasma
Zeitfenster: on day 1, day 3, and day 6
|
on day 1, day 3, and day 6
|
To test the prognostic value of soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1, S100A12, AGEs) levels in ICU patients with ALI/ARDS:
Zeitfenster: on day 28
|
on day 28
|
To test the correlation between biomarkers levels (soluble forms (sRAGE, esRAGE) and ligands of RAGE (HMGB-1,
Zeitfenster: on day 1, day 3, and day 6.
|
on day 1, day 3, and day 6.
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Mechanische Lüftung
- Akute Atemnotsyndrom (ARDS)
- Intensivstation (ICU)
- Akute Lungenverletzung (ALI)
- Rezeptor für Endprodukte der fortgeschrittenen Glykation (RAGE)
- Löslicher RAGE (sRAGE)
- Alveolarepithel
- Endogenous secretory RAGE (esRAGE)
- High-mobility group box-1 protein (HMGB-1)
- Extracellular newly-identified RAGE-binding protein (EN-RAGE or S100A12)
- Advanced glycation endproducts (AGEs)
- Pentosidine
- N--carboxymethyllysine
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CHU-0086
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Akutes Lungenversagen
-
The University of Hong KongHong Kong Buddhist AssociationAbgeschlossenPostprandiales Distress-SyndromHongkong
-
Xiyuan Hospital of China Academy of Chinese Medical...The First Affiliated Hospital, Guangzhou University of Traditional Chinese... und andere MitarbeiterUnbekanntPostprandiales Distress-SyndromChina
-
Procter and GambleARYx TherapeuticsBeendetPostprandiales Distress-SyndromVereinigte Staaten, Kanada, Vereinigtes Königreich
-
Xiyuan Hospital of China Academy of Chinese Medical...RekrutierungFunktionelle Dyspepsie | Postprandiales Distress-SyndromChina, Australien
-
Chengdu University of Traditional Chinese MedicineChongqing Medical University; Hunan University of Traditional Chinese MedicineAbgeschlossenFunktionelle Dyspepsie | Postprandiales Distress-SyndromChina
-
Lotung Poh-Ai HospitalTomorrow Medical FoundationAbgeschlossenFunktionelle Dyspepsie | Epigastrisches Schmerzsyndrom | Postprandiales Distress-SyndromTaiwan
-
University of AarhusAnmeldung auf EinladungKörperliches Distress-Syndrom | Funktionsstörung | Mehrfache chemische EmpfindlichkeitDänemark
-
Regionshospitalet SilkeborgAarhus University HospitalRekrutierungKörperliches Distress-Syndrom | Funktionelle somatische StörungDänemark
-
University of MinnesotaNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...RekrutierungGrippe | Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)Vereinigte Staaten, Australien, Spanien, Dänemark, Griechenland, Argentinien, Vereinigtes Königreich, Belgien, Chile, Deutschland, Peru, Thailand
-
Fondazione Policlinico Universitario Agostino Gemelli...AbgeschlossenEntwöhnungsfehler | Distress Respiratory Syndrome